Skip to main content
Free research Free research Free assay review with research home and workspace preview
Quick search ChEMBL 36
Assay Detail

CHEMBL3767620

Review assay metadata, readout intent, target linkage, and publication context from the same page.

Binding
Inhibition of c-Met (unknown origin)
13
Total Activities
13
Compounds Tested
2
Activity Types
0
Assay Parameters

Assay Information

Assay Type Binding
Organism Homo sapiens
Confidence 9 — Direct single protein target
Curated By Autocuration

Target

Hepatocyte growth factor receptor (CHEMBL3717)
Type SINGLE PROTEIN
Organism Homo sapiens

Publication

Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.
Zhang J, Jiang X, Jiang Y, Guo M, Zhang S, Li J, He J, Liu J, Wang J, Ouyang L.
Eur J Med Chem (2016) 108 : 495 -504
PubMed 26717201 · DOI

Activity Statistics

Type Count Avg pChEMBL Best pChEMBL
IC50 10 8.53 9.89
Ki 3 7.92 8.92

Compounds Tested

Compound Name Phase Activities Best pChEMBL
CHEMBL3188267 CAPMATINIB 4.0 1 9.89
CHEMBL1822792 MK-2461 2.0 1 9.40
CHEMBL460472 1 8.92
CHEMBL3402762 TEPOTINIB 4.0 1 8.52
CHEMBL460702 BMS-777607 2.0 1 8.41
CHEMBL601719 CRIZOTINIB 4.0 1 8.40
CHEMBL1236107 SGX-523 1.0 1 8.40
CHEMBL2133806 JNJ-38877605 1.0 1 8.40
CHEMBL2001019 PF-04217903 1.0 1 8.32
CHEMBL450786 PHA-665752 1 8.05
CHEMBL496102 AMG-208 2.0 1 8.05
CHEMBL1738731 1 7.85
CHEMBL2103882 TIVANTINIB 3.0 1 6.45

Activity Data

Compound Name Type Rel. Value Units pChEMBL
CHEMBL3188267 CAPMATINIB IC50 = 0.13 nM 9.89
CHEMBL1822792 MK-2461 IC50 = 0.4 nM 9.40
CHEMBL460472 Ki = 1.2 nM 8.92
CHEMBL3402762 TEPOTINIB IC50 = 3.0 nM 8.52
CHEMBL460702 BMS-777607 IC50 = 3.9 nM 8.41
CHEMBL601719 CRIZOTINIB Ki = 4.0 nM 8.40
CHEMBL1236107 SGX-523 IC50 = 4.0 nM 8.40
CHEMBL2133806 JNJ-38877605 IC50 = 4.0 nM 8.40
CHEMBL2001019 PF-04217903 IC50 = 4.8 nM 8.32
CHEMBL450786 PHA-665752 IC50 = 9.0 nM 8.05
CHEMBL496102 AMG-208 IC50 = 9.0 nM 8.05
CHEMBL1738731 IC50 = 14.0 nM 7.85
CHEMBL2103882 TIVANTINIB Ki = 355.0 nM 6.45